Business
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid a...
About this update from Adaptogenics Health Corp.
[{"type":"text","content":"Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer\n\n\n\n\n A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis\n \n\n\n\n A data licensing agreement to access Adaptive’s proprietary TCR-antigen datasets for research and development in multiple immunology applications\n \n\n\n SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptive’s proprietary T-cell receptor (TCR) discovery capabilities and large-scale immune receptor antigen mapping data.\n \n\n\n Discovering disease-causing TCRs in rheumatoid arthritis\n \n\n\n Adaptive has identified autoreactive or ‘offender’ TCRs that could potentially cause disease in patients with autoimmune indications.\n \n\n Pfizer will utilize Adaptive’s immune medicine platform to identify disease-causing TCRs as potential therapeutic targets in rheumatoid arthritis (RA). Under this agreement, Adaptive will apply its platform to Pfizer’s clinical samples to identify the subset of common TCRs that are significantly enriched in RA patients. Pfizer will use these data to accelerate its research and development of potential therapeutic candidates for RA.\n \n\n\n Licensing Adaptive’s TCR-antigen datasets\n \n\n\n Adaptive has generated what it believes is the largest and highest quality TCR-antigen binding dataset relative to what is publicly available. Under this agreement, Pfizer has licensed certain Adaptive TCR-antigen data for its use in developing and training Pfizer’s AI and machine learning models to accelerate research and drug discovery in multiple disease areas.\n \n\n “Using our AI-enabled immune medicine platform, Adaptive has amassed a treasure trove of immune receptor data along with an enhanced understanding of T-cell biology,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “This deep and well-characterized immune system data has the potential to inform discoveries across immunology programs...